Treating in the Dark: Unanswered Questions on Costs and Benefits of Late Line Therapy for Metastatic Breast Cancer

ISSN： 0735-7907

Source： Cancer Investigation, Vol.27, Iss.1, 2009-01, pp. : 13-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vinorelbine, Epirubicin and Fluorouracil as First-Line Therapy in Metastatic Breast Cancer

By Elomaa Inkeri Joensuu Heikki Blomqvist Carl

Acta Oncologica, Vol. 42, Iss. 4, 2003-01 ,pp. : 309-314

Informa Healthcare

Access to resources Recommend Favorite

Taxanes in the Adjuvant Treatment of Early Breast Cancer, Emerging Consensus and Unanswered Questions

By Tang Shou-Ching

Cancer Investigation, Vol. 27, Iss. 5, 2009-06 ,pp. : 489-495

Informa Healthcare

Access to resources Recommend Favorite

Health System Costs of Metastatic Breast Cancer

By Wai E.S.

Breast Cancer Research and Treatment, Vol. 65, Iss. 3, 2001-02 ,pp. : 233-240

Springer Publishing Company

Access to resources Recommend Favorite

Unanswered questions in screening for prostate cancer

By Neal D.E. Leung H.Y. Powell P.H. Hamdy F.C. Donovan J.L.

European Journal of Cancer, Vol. 36, Iss. 10, 2000-06 ,pp. : 1316-1321

Elsevier

Access to resources Recommend Favorite

Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study

The Women's Oncology Review, Vol. 4, Iss. 4, 2004-12 ,pp. : 283-285

Informa Healthcare

Access to resources Recommend Favorite